Advanced Cell Technology, Incorporated is a biotechnology company located in Marlborough, Massachusetts, USA. The company specializes in the development and commercialization of cell therapies for the treatment of a variety of diseases. ACT is primarily developing stem cell-based technologies, both adult and human embryonic, and other methods and treatments in the area of regenerative medicine.ACT's Chief Scientific Officer is Robert Lanza, who is also Adjunct Professor at Wake Forest University School of Medicine. Lanza and Harvard faculty member George Church are joining forces to start an animal de-extinction startup named Ark.On June 24, 2014, ACT announced that Paul K. Wotton, previously of Antares Pharma Inc , will become President and Chief Executive Officer, effective July 21, 2014. Wikipedia.
Advanced Cell Technology | Date: 2014-10-28
This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.
Advanced Cell Technology | Date: 2017-02-17
Methods for de-differentiating or altering the life-span of desired recipient cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
Advanced Cell Technology | Date: 2014-05-07
An improved method of producing differentiated progenitor cells comprising obtaining inner cell mass cells from a blastocyst and inducing differentiation of the inner cell mass cells to produce differentiated progenitor cells. The differentiated progenitor cells may be transfected such that there is an addition, deletion or alteration of a desired gene. The differentiated progenitor cells are useful in cell therapy and as a I source of cells for the production of tissues and organs for transplantation. Also provided is a method of producing a lineage-defective human embryonic stem cell.
Advanced Cell Technology | Date: 2014-10-01
The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.
Advanced Cell Technology | Date: 2016-02-10
The present invention relates generally to the field of somatic cell nuclear transfer (SCNT) and to the creation of cloned animals and cells. The disclosure relates to a method of cloning a mammal, obtaining pluripotent cells such as embryonic stem cells, or for reprogramming a mammalian cell using an oocyte and a fertilized embryo.
Advanced Cell Technology | Date: 2016-08-25
This invention generally relates to methods to differentiate pluripotent stem cells, such as embryonic stem, embryonic germ, or embryo-derived cells, to obtain subpopulations of cells from heterogeneous mixtures of cells wherein the subpopulation of cells possess reduced differentiation potential compared to the original pluripotent stem cells and where the subpopulation is capable of being propagated.
Advanced Cell Technology | Date: 2016-04-29
The invention relates to assays for screening growth factors, adhesion molecules, immunostimulatory molecules, extracellular matrix components and other materials, alone or in combination, simultaneously or temporally, for the ability to induce directed differentiation of pluripotent and multipotent stem cells.
Advanced Cell Technology | Date: 2014-03-27
This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
Advanced Cell Technology | Date: 2014-09-17
Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.
Advanced Cell Technology | Date: 2014-04-30
This present invention provides novel methods for deriving embryonic stem cells and embryo-derived cells from an embryo without requiring destruction of the embryo. The invention further provides cells and cell lines derived without embryo destruction, and the use of the cells for therapeutic and research purposes. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.